Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients

被引：11
|
作者：
Trombetta, Claudia Maria [1 ]
Marchi, Serena [1 ]
Viviani, Simonetta [1 ]
Manenti, Alessandro [2 ]
Benincasa, Linda [3 ]
Ruello, Antonella [4 ]
Bombardieri, Emilio [4 ]
Vicenti, Ilaria [5 ]
Zazzi, Maurizio [5 ]
Montomoli, Emanuele [1 ,2 ,3 ]
机构：
[1] Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy
[2] VisMederi Srl, Str Petriccio & Belriguardo 35, I-53100 Siena, Italy
[3] VisMederi Res Srl, Str Petriccio & Belriguardo 35, I-53100 Siena, Italy
[4] Humanitas Gavazzeni, Via Mauro Gavazzeni 21, I-24125 Bergamo, Italy
[5] Univ Siena, Dept Med Biotechnol, I-53100 Siena, Italy
来源：
VIRUSES-BASEL | 2021年 / 13卷 / 07期
基金：
欧盟地平线“2020”;
关键词：
neutralizing activity; SARS-CoV-2; variants of concern;
D O I：
10.3390/v13071347
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The recent spreading of new SARS-CoV-2 variants, carrying several mutations in the spike protein, could impact immune protection elicited by natural infection or conferred by vaccination. In this study, we evaluated the neutralizing activity against the viral variants that emerged in the United Kingdom (B.1.1.7), Brazil (P.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020. Of the patients studied, 59.5% showed a decrease (>= 2 fold) in neutralizing antibody titer against B.1.1.7, 83.3% against P.1, and 90.5% against B.1.351 with respect to the original strain. The reduction in antibody titers against all analyzed variants, and in particular P.1 and B.1.351, suggests that previous symptomatic infection might be not fully protective against exposure to SARS-CoV-2 variants carrying a set of relevant spike mutations.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
    Planas, Delphine
    Bruel, Timothee
    Grzelak, Ludivine
    Guivel-Benhassine, Florence
    Staropoli, Isabelle
    Porrot, Francoise
    Planchais, Cyril
    Buchrieser, Julian
    Rajah, Maaran Michael
    Bishop, Elodie
    Albert, Melanie
    Donati, Flora
    Prot, Matthieu
    Behillil, Sylvie
    Enouf, Vincent
    Maquart, Marianne
    Smati-Lafarge, Mounira
    Varon, Emmanuelle
    Schortgen, Frederique
    Yahyaoui, Layla
    Gonzalez, Maria
    De Seze, Jerome
    Pere, Helene
    Veyer, David
    Seve, Aymeric
    Simon-Loriere, Etienne
    Fafi-Kremer, Samira
    Stefic, Karl
    Mouquet, Hugo
    Hocqueloux, Laurent
    van der Werf, Sylvie
    Prazuck, Thierry
    Schwartz, Olivier
    [J]. NATURE MEDICINE, 2021, 27 (05) : 917 - +
  • [2] Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
    Delphine Planas
    Timothée Bruel
    Ludivine Grzelak
    Florence Guivel-Benhassine
    Isabelle Staropoli
    Françoise Porrot
    Cyril Planchais
    Julian Buchrieser
    Maaran Michael Rajah
    Elodie Bishop
    Mélanie Albert
    Flora Donati
    Matthieu Prot
    Sylvie Behillil
    Vincent Enouf
    Marianne Maquart
    Mounira Smati-Lafarge
    Emmanuelle Varon
    Frédérique Schortgen
    Layla Yahyaoui
    Maria Gonzalez
    Jérôme De Sèze
    Hélène Péré
    David Veyer
    Aymeric Sève
    Etienne Simon-Lorière
    Samira Fafi-Kremer
    Karl Stefic
    Hugo Mouquet
    Laurent Hocqueloux
    Sylvie van der Werf
    Thierry Prazuck
    Olivier Schwartz
    [J]. Nature Medicine, 2021, 27 : 917 - 924
  • [3] Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
    Wang, Pengfei
    Nair, Manoj S.
    Liu, Lihong
    Iketani, Sho
    Luo, Yang
    Guo, Yicheng
    Wang, Maple
    Yu, Jian
    Zhang, Baoshan
    Kwong, Peter D.
    Graham, Barney S.
    Mascola, John R.
    Chang, Jennifer Y.
    Yin, Michael T.
    Sobieszczyk, Magdalena
    Kyratsous, Christos A.
    Shapiro, Lawrence
    Sheng, Zizhang
    Huang, Yaoxing
    Ho, David D.
    [J]. NATURE, 2021, 593 (7857) : 130 - +
  • [4] Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
    Pengfei Wang
    Manoj S. Nair
    Lihong Liu
    Sho Iketani
    Yang Luo
    Yicheng Guo
    Maple Wang
    Jian Yu
    Baoshan Zhang
    Peter D. Kwong
    Barney S. Graham
    John R. Mascola
    Jennifer Y. Chang
    Michael T. Yin
    Magdalena Sobieszczyk
    Christos A. Kyratsous
    Lawrence Shapiro
    Zizhang Sheng
    Yaoxing Huang
    David D. Ho
    [J]. Nature, 2021, 593 : 130 - 135
  • [5] SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
    Hoffmann, Markus
    Arora, Prerna
    Gross, Rudiger
    Seidel, Alina
    Hornich, Bojan F.
    Hahn, Alexander S.
    Kruger, Nadine
    Graichen, Luise
    Hofmann-Winkler, Heike
    Kempf, Amy
    Winkler, Martin S.
    Schulz, Sebastian
    Jack, Hans-Martin
    Jahrsdorfer, Bernd
    Schrezenmeier, Hubert
    Muller, Martin
    Kleger, Alexander
    Munch, Jan
    Pohlmann, Stefan
    [J]. CELL, 2021, 184 (09) : 2384 - +
  • [6] Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
    Munster, Vincent J.
    Flagg, Meaghan
    Singh, Manmeet
    Yinda, Claude Kwe
    Williamson, Brandi N.
    Feldmann, Friederike
    Perez-Perez, Lizzette
    Schulz, Jonathan
    Brumbaugh, Beniah
    Holbrook, Myndi G.
    Adney, Danielle R.
    Okumura, Atsushi
    Hanley, Patrick W.
    Smith, Brian J.
    Lovaglio, Jamie
    Anzick, Sarah L.
    Martens, Craig
    van Doremalen, Neeltje
    Saturday, Greg
    de Wit, Emmie
    [J]. SCIENCE ADVANCES, 2021, 7 (43):
  • [7] PREDOMINANCE OF SARS-COV-2 B.1.1.7 AND B.1.351 VARIANTS IN METRO MANILA, PHILIPPINES
    Velasco, John Mark S.
    Valderama, Ma. Theresa
    Diones, Paula Corazon
    Leonardia, Susie
    Klungthong, Chonticha
    Joonlasak, Khajohn
    Manasatienkij, Wudtichai
    Chinnawirotpisan, Piyawan
    Huang, Angkana
    Jones, Anthony
    Fernandez, Stefan
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 196 - 196
  • [8] Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
    Gushchin, Vladimir A.
    Dolzhikova, Inna, V
    Shchetinin, Alexey M.
    Odintsova, Alina S.
    Siniavin, Andrei E.
    Nikiforova, Maria A.
    Pochtovyi, Andrei A.
    Shidlovskaya, Elena, V
    Kuznetsova, Nadezhda A.
    Burgasova, Olga A.
    Kolobukhina, Liudmila, V
    Iliukhina, Anna A.
    Kovyrshina, Anna, V
    Botikov, Andrey G.
    Kuzina, Aleksandra, V
    Grousova, Daria M.
    Tukhvatulin, Amir, I
    Shcheblyakov, Dmitry, V
    Zubkova, Olga, V
    Karpova, Oksana, V
    Voronina, Olga L.
    Ryzhova, Natalia N.
    Aksenova, Ekaterina, I
    Kunda, Marina S.
    Lioznov, Dmitry A.
    Danilenko, Daria M.
    Komissarov, Andrey B.
    Tkachuck, Artem P.
    Logunov, Denis Y.
    Gintsburg, Alexander L.
    [J]. VACCINES, 2021, 9 (07)
  • [9] Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)
    Trimpert, Jakob
    Adler, Julia M.
    Eschke, Kathrin
    Abdelgawad, Azza
    Firsching, Theresa C.
    Ebert, Nadine
    Tran Thi Nhu Thao
    Gruber, Achim D.
    Thiel, Volker
    Osterrieder, Nikolaus
    Kunec, Dusan
    [J]. SCIENCE ADVANCES, 2021, 7 (49):
  • [10] In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
    Jungnick, Sabrina
    Hobmaier, Bernhard
    Mautner, Lena
    Hoyos, Mona
    Haase, Maren
    Baiker, Armin
    Lahne, Heidi
    Eberle, Ute
    Wimmer, Clara
    Hepner, Sabrina
    Sprenger, Annika
    Berger, Carola
    Dangel, Alexandra
    Ippisch, Siegfried
    Hahner, Sonja
    Wildner, Manfred
    Liebl, Bernhard
    Ackermann, Nikolaus
    Sing, Andreas
    Fingerle, Volker
    [J]. MICROORGANISMS, 2021, 9 (09)
12345